Interview with Dieter Torheiden, Managing Director, Solvay Australia
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
Address: 20-22 McPherson St, Banksmeadow 2019, NSW,,Australia
Tel: 61-2-93168000
Web: http://www.solvayinterox.com.au/
Solvay Interox is the world’s leading producer of hydrogen peroxide and its derivatives, with production facilities worldwide. Solvay Interox Pty Ltd in Australia is wholly owned by Solvay and is a member of the worldwide Solvay Group of chemical and pharmaceutical companies. Solvay Interox in Australia is based in Banksmeadow, NSW and serves the peroxygen needs of Australia, New Zealand and the SW Pacific Islands. Solvay Interox’s Quality Management System is registered to the ISO 9002:1994 International Quality Standard for our hydrogen peroxide manufacturing facility and supporting corporate functions. We also actively support the Responsible Care ® initiative as a priority business guideline.
Hydrogen Peroxide
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our readers an introduction to…
In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is going through globally: the country deals with patent cliffs, companies are…
See our Cookie Privacy Policy Here
